Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Drugs in Development, 2021

September 2021 | 128 pages | ID: TE80CFCCD75DEN
Global Markets Direct

Abstracts

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Drugs in Development, 2021

SUMMARY

Transthyretin (ATTR or Prealbumin or TBPA or TTR) pipeline Target constitutes close to 18 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The latest report Transthyretin - Drugs In Development, 2021, outlays comprehensive information on the Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Transthyretin is a transport protein. It transports thyroid hormones in the plasma and cerebrospinal fluid, and also transports retinol (vitamin A) in the plasma. The diseases caused by mutations include amyloidotic polyneuropathy, euthyroid hyperthyroxinaemia, amyloidotic vitreous opacities, cardiomyopathy, oculoleptomeningeal amyloidosis, meningocerebrovascular amyloidosis and carpal tunnel syndrome. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4, 4 and 2 respectively. Similarly, the universities portfolio in Phase III and Phase I stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Cardiovascular, Gastrointestinal, Immunology and Infectious Disease which include indications Familial Amyloid Neuropathies, Amyloidosis, Familial Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Alzheimer's Disease, Cardiomyopathy, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Crohn's Disease (Regional Enteritis), Multiple Sclerosis, Rheumatoid Arthritis and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
• The report reviews Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics and enlists all their major and minor projects
• The report assesses Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Transthyretin (ATTR or Prealbumin or TBPA or TTR)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Transthyretin (ATTR or Prealbumin or TBPA or TTR) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Overview
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Development
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Assessment
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Companies Involved in Therapeutics Development
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Drug Profiles
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Dormant Projects
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Discontinued Products
Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by ADRx Inc, 2021
Pipeline by Akcea Therapeutics Inc, 2021
Pipeline by Alnylam Pharmaceuticals Inc, 2021
Pipeline by Autotac Bio Inc, 2021
Pipeline by BridgeBio Pharma Inc, 2021
Pipeline by Corino Therapeutics Inc, 2021
Pipeline by Covalent Bioscience Inc, 2021
Pipeline by Neurimmune Holding AG, 2021
Pipeline by Novo Nordisk AS, 2021
Pipeline by Precision Biosciences Inc, 2021
Pipeline by Proclara Biosciences Inc, 2021
Pipeline by Regeneron Pharmaceuticals Inc, 2021
Pipeline by Vera Therapeutics Inc, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021